A glucagon-like peptide 2 analogue promotes growth of intestinal mucosa.
Trade name Gattex.
Restores intestinal structural functional integrity , reduces gastric emptying and secretion.
Reduces volumes and parenteral nutritional support in patients with short bowel syndrome with intestinal failure (Jeppesen P et al ).
Can make abnormal cells grow faster.
Can possibly accelerate neoplastic growth and enhance growth of colorectal polyps.
Maybe associated with gastrointestinal obstruction, gallbladder, biliary tract and pancreatic disease.
6.4% of treated patients report biliary events, including cholecystitis, gallstones, and sludge.
Patient should have a colonoscopy prior to use of this drug and any polyps should be removed.
May be associated with fluid overload, abdominal pain or swelling, local skin reaction at the site of the injection, nausea, headache, and vomiting.
13.3% of patients treated with this agent have fluid overwhelmed.
May be associated with increased absorption of fluids and increased absorption of oral medications with narrow therapeutic index.
Parenteral nutrition and IV fluid volume should be suggested to prevent fluid overload.
Promotes growth of intestinal epithelial cells in the G.I. tract.
2.3% of patients treated developed G.I. polyps.
1.7% of patients develop pancreatitis while on treatment.
Dose 0.05 mg per kilogram per day subcutaneously.